Compare Intuit Inc. (INTU) vs Summit Therapeutics Inc (SMMT) Price & Performance

Intuit (INTU) trades at $336.44, up 0.6% today, with a bullish technical signal from moving averages and oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $12.8 exceeding expectations. Revenue grew to $18.83B in 2025, with a net income margin of 21.91%. However, the stock faces headwinds from multiple law firm investigations into securities fraud allegations related to pricing issues, contributing to a 20% stock drop recently noted by Forbes on June 2, 2026.

The outlook is mixed: robust fundamentals and a consensus price target of $402.26 suggest upside, but legal risks and overbought RSI levels near 81.6 pose near-term challenges. Investors should weigh the company's AI-driven growth in financial software against regulatory scrutiny and competitive pressures in the fintech space.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.